Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta

Applied Microbiology and Biotechnology

Volumn 100, Issue 7, 2016, Pages 3035-3047

  Jia, Dianlong ^a   Yang, Hao ^a   Tao, Ze ^a   Wan, Lin ^a   Cheng, Jingqiu ^a   Lu, Xiaofeng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Anticancer drug; Apoptosis; Cancer biotherapy; Rhesus monkey; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CELL DEATH; CLONING; DISEASES; DISSOCIATION; DYNAMIC LIGHT SCATTERING; ESCHERICHIA COLI; GENE ENCODING; GLYCOPROTEINS; LIGANDS; LIGHT SCATTERING; MACROPHAGES; TUMORS;

AMINO ACID SEQUENCE; ANTICANCER DRUG; CANCER BIOTHERAPY; DISSOCIATION RATES; EXTRACELLULAR DOMAINS; NANOMOLAR AFFINITY; RHESUS MONKEY; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDS;

SIZE EXCLUSION CHROMATOGRAPHY;

BORTEZOMIB; CASPASE; DEATH RECEPTOR; N BROMOSUCCINIMIDE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; TNFSF10 PROTEIN, HUMAN;

BIOTECHNOLOGY; CANCER; CELLS AND CELL COMPONENTS; CHROMATOGRAPHY; DRUG; GENE EXPRESSION; LIGAND; LIGHT SCATTERING; PRIMATE; PROTEIN; TEMPERATURE EFFECT; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; ESCHERICHIA COLI; HUMAN; HUMAN CELL; JURKAT CELL LINE; LOW TEMPERATURE; MOLECULAR SIZE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRECIPITATION; RHESUS MONKEY; ROOM TEMPERATURE; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR CLONING; PATHOLOGY; PROTEIN DOMAIN; SOLUBILITY; SPECIES DIFFERENCE; TUMOR CELL LINE;

ESCHERICHIA COLI; MACACA MULATTA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BROMOSUCCINIMIDE; CASPASES; CELL LINE, TUMOR; CHEMICAL PRECIPITATION; CLONING, MOLECULAR; COLONIC NEOPLASMS; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACACA MULATTA; MICE; MOLECULAR WEIGHT; PROTEIN DOMAINS; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; SOLUBILITY; SPECIES SPECIFICITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960804960     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-015-7143-7     Document Type: Article

References (25)

1. Audo R, Combe B, Hahne M, Morel J (2013) The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. Cytokine 63:81–90
2. Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL (2010) Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin’s lymphoma (NHL). J Clin. Oncol 28 (15 s): abstr 8104
3. Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC, Sung YC, Oh BH (1999) 2.8 a resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11(2):253–261
4. Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, Lee MS, Oh BH (2000) Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem 275(40):31171–31177
5. Chen Q, Wang C, Zhan ZX, He WW, Cheng ZP, Li YY, Liu Z (2014) Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy. Biomaterials 35:8206–8214
6. den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, de Vries EG (2013) Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 332:194–201
7. 131I- and CF750-labeled dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors. Biomed Res Int 2014:459676
8. Finnberg N, Klein-Szanto AJ, El-Deiry WS (2008) TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 118:111–123
9. Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM, Moshkovskii SA, Kirpichnikov P (2009) Generation of new TRAIL mutants DR5-a and DR5-B with improved selectivity to death receptor 5. Apoptosis 14:778–787
10. Goyal M, Chaudhuri TK, Kuwajima K (2014) Irreversible denaturation of maltodextrin glucosidase studied by differential scanning calorimetry, circular dichroism, and turbidity measurements. PLoS One 9(12):e115877
11. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O’Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839–2846
12. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O’Connell M, Kelley RF, Ashkenazi A, de Vos AM (1999) Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4(4):563–571
13. Hymowitz SG, O’Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF (2000) A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39:633–640
14. Jia D, Yang H, Wan L, Cheng J, Lu X (2012) Production of bioactive, SUMO-modified, and native-like TNF-α of the rhesus monkey, macaca mulatta, in Escherichia coli. Appl Microbiol Biotechnol 93:2345–2355
15. Kasubhai SM, Bendell JC, Kozloff M, Kapp AM, Ashkenazi A, Royer-Joo S, Portera CC (2012) Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 30 (15 s): abstr 3543
16. Kozloff M, Messersmith WA, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Wainberg ZA (2012) Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 30 (15 s): abstr 3552
17. Ming X, Carver K, Wu L (2013) Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials 34:7939–7949
18. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY, Screaton GR (1999) Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 6(11):1048–1053
19. Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, Blackhall F (2011) Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 29:4442–4451
20. Stuckey DW, Shah K (2013) TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 19:685–694
21. Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A, Serrano L, Quax WJ (2008) DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 283:20560–20568
22. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A 103:8634–8639
23. Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, Krech T, Kontermann R, Manns MP, Schulze-Osthoff K, Pfizenmaier K, Bantel H (2013) Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 57(2):625–636
24. Wajant H, Gerspach J, Pfizenmaier K (2013) Engineering death receptor ligands for cancer therapy. Cancer Lett 332:163–174
25. Yang H, Cai H, Wan L, Liu S, Li S, Cheng J, Lu X (2013) Bombesin Analogue-mediated Delivery Preferentially Enhances the Cytotoxicity of a Mitochondria-Disrupting Peptide in Tumor Cells PLoS One:8e57358